The FDA has approved Rezdiffra (resmetirom) for the treatment of noncirrhotic non-alcoholic steatohepatitis (NASH), also known as fatty liver disease. This approval, under the FDA’s Accelerated Approval program, is based on Phase III data showing Rezdiffra’s efficacy in reducing fat accumulating in the liver. (Source: European Pharmaceutical Review)
Stroke experts to test emerging nerve stimulation treatment
A new stroke therapy that delivers electrical pulses to the brain via a portable device will be tested in a pioneering trial to improve arm recovery after stroke. Led by researchers from Sheffield Teaching Hospitals NHS Foundation Trust and the University of Sheffield, this trial aims to determine if transcutaneous vagus nerve stimulation can enhance hand and arm strength during rehabilitation therapy for stroke survivors. (Source: PharmaTimes)
